CASI Pharmaceuticals Inc. (CASI)
(Delayed Data from NSDQ)
$3.25 USD
-0.03 (-0.76%)
Updated May 16, 2024 02:11 PM ET
After-Market: $3.28 +0.04 (1.08%) 6:18 PM ET
3-Hold of 5 3
C Value F Growth NA Momentum NA VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CASI 3.25 -0.03(-0.76%)
Will CASI be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CASI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CASI
USANA Health Sciences (USNA) Q3 Earnings Miss Estimates
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates (Revised)
CASI: What are Zacks experts saying now?
Zacks Private Portfolio Services
ProPhase Labs, Inc. (PRPH) Reports Q2 Loss, Lags Revenue Estimates
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
Other News for CASI
Casi Pharma spikes as FDA clears clinical trial for blood disorder therapy
CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Casi receives permission to proceed with CID-103 study from FDA
CASI Pharmaceuticals: A Buy Rating Amid Financial and Clinical Promise